<i>TARDBP</i> mutations in motoneuron disease with frontotemporal lobar degenerationLina Benajiba, Alexis Brice, Didier Hannequin et al.|Annals of Neurology|2009Cited by 302
<i>SOD1</i>, <i>ANG</i>, <i>VAPB</i>, <i>TARDBP</i>, and <i>FUS</i> mutations in familial amyotrophic lateral sclerosis: genotype–phenotype correlationsStéphanie Millecamps, Vincent Meininger, François Salachas et al.|Journal of Medical Genetics|2010Cited by 296
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, Massimo Locati, P. Nigel Leigh et al.|The Lancet|2025Cited by 33
Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2Ilaria Giovannelli, Janine Kirby, Nadhim Bayatti et al.|Brain Communications|2021Cited by 28